FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128294524> ?p ?o ?g. }

• W3128294524 endingPage "3416" @default.
• W3128294524 startingPage "3392" @default.
• W3128294524 abstract "Rationale: Immune checkpoint inhibitors (ICIs) against the PD-1/PD-L1 pathway showed limited success in non-small cell lung cancer (NSCLC) patients, especially in those with activating epidermal growth factor receptor (EGFR) mutations. Elucidation of the mechanisms underlying EGFR-mediated tumor immune escape and the development of effective immune therapeutics are urgently needed. Immunoglobulin-like transcript (ILT) 4, a crucial immunosuppressive molecule initially identified in myeloid cells, is enriched in solid tumor cells and promotes the malignant behavior of NSCLC. However, the upstream regulation of ILT4 overexpression and its function in tumor immunity of NSCLC with EGFR activation remains unclear. Methods: ILT4 expression and EGFR phosphorylation in human NSCLC tissues and cell lines were analyzed using immunohistochemistry (IHC), real-time PCR, Western blotting, immunofluorescence, and flow cytometry. The molecular signaling for EGFR-regulated ILT4 expression was investigated using mRNA microarray and The Cancer Genome Atlas (TCGA) database analyses and then confirmed by Western blotting. The regulation of tumor cell proliferation and apoptosis by ILT4 was examined by CCK8 proliferation and apoptosis assays. The impact of ILT4 and PD-L1 on tumor-associated macrophage (TAM) recruitment and polarization was evaluated using Transwell migration assay, flow cytometry, enzyme linked immunosorbent assay (ELISA) and real-time PCR, while their impact on T cell survival and cytotoxicity was analyzed by CFSE proliferation assay, apoptotic assay, flow cytometry, ELISA and cytolytic assay. Tumor immunotherapy models targeting at paired Ig-like receptor B (PIR-B, an ortholog of ILT4 in mouse)/ILT4 and/or PD-L1 were established in C57BL/6 mice inoculated with stable EGFR- overexpressing Lewis lung carcinoma (LLC) cells and in humanized NSG mice inoculated with EGFR mutant, gefitinib-resistant PC9 (PC9-GR) or EGFR-overexpressing wild type H1299 cells. PIR-B and ILT4 inhibition was implemented by infection of specific knockdown lentivirus and PD-L1 was blocked using human/mouse neutralizing antibodies. The tumor growth model was established in NSG mice injected with PIR-B-downregulated LLC cells to evaluate the effect of PIR-B on tumor proliferation. The frequencies and phenotypes of macrophages and T cells in mouse spleens and blood were detected by flow cytometry while those in tumor tissues were determined by IHC and immunofluorescence. Results: We found that ILT4 expression in tumor cells was positively correlated with EGFR phosphorylation in human NSCLC tissues. Using NSCLC cell lines, we demonstrated that ILT4 was upregulated by both tyrosine kinase mutation-induced and epidermal growth factor (EGF)-dependent EGFR activation and subsequent AKT/ERK1/2 phosphorylation. Overexpressed ILT4 in EGFR-activated tumor cells induced TAM recruitment and M2-like polarization, which impaired T cell function. ILT4 also directly inhibited T cell proliferation, cytotoxicity, and IFN-γ expression and secretion. In EGFR-activated cell lines in vitro and in wild-type EGFR-activated C57BL/6 and humanized NSG immunotherapy models in vivo, either ILT4 (PIR-B) or PD-L1 inhibition enhanced anti-tumor immunity and suppressed tumor progression by counteracting TAM- and dysfunctional T cell- induced immuno-suppressive TME; the combined inhibition of both molecules showed the most dramatic tumor retraction. Surprisingly, in EGFR mutant, TKI resistant humanized NSG immunotherapy model, ILT4 inhibition alone rather than in combination with a PD-L1 inhibitor suppressed tumor growth and immune evasion. Conclusions: ILT4 was induced by activation of EGFR-AKT and ERK1/2 signaling in NSCLC cells. Overexpressed ILT4 suppressed tumor immunity by recruiting M2-like TAMs and impairing T cell response, while ILT4 inhibition prevented immunosuppression and tumor promotion. Furthermore, ILT4 inhibition enhanced the efficacy of PD-L1 inhibitor in EGFR wild-type but not in EGFR mutant NSCLC. Our study identified novel mechanisms for EGFR-mediated tumor immune escape, and provided promising immunotherapeutic strategies for patients with EGFR-activated NSCLC." @default.
• W3128294524 created "2021-02-15" @default.
• W3128294524 creator A5006148444 @default.
• W3128294524 creator A5014030303 @default.
• W3128294524 creator A5019707913 @default.
• W3128294524 creator A5023113049 @default.
• W3128294524 creator A5030908494 @default.
• W3128294524 creator A5043713844 @default.
• W3128294524 creator A5064711465 @default.
• W3128294524 creator A5081953823 @default.
• W3128294524 creator A5082553528 @default.
• W3128294524 creator A5083090225 @default.
• W3128294524 creator A5086271283 @default.
• W3128294524 creator A5088114400 @default.
• W3128294524 date "2021-01-01" @default.
• W3128294524 modified "2023-10-16" @default.
• W3128294524 title "ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation" @default.
• W3128294524 cites W1966930760 @default.
• W3128294524 cites W1971620413 @default.
• W3128294524 cites W1989438472 @default.
• W3128294524 cites W2044835625 @default.
• W3128294524 cites W2047086643 @default.
• W3128294524 cites W2056973714 @default.
• W3128294524 cites W2058648826 @default.
• W3128294524 cites W2077689069 @default.
• W3128294524 cites W2087690546 @default.
• W3128294524 cites W2099528380 @default.
• W3128294524 cites W2120944127 @default.
• W3128294524 cites W2135915203 @default.
• W3128294524 cites W2140112018 @default.
• W3128294524 cites W2147592245 @default.
• W3128294524 cites W2150633526 @default.
• W3128294524 cites W2166084034 @default.
• W3128294524 cites W2314057593 @default.
• W3128294524 cites W2406354551 @default.
• W3128294524 cites W2527905628 @default.
• W3128294524 cites W2596760231 @default.
• W3128294524 cites W2725037490 @default.
• W3128294524 cites W2740806763 @default.
• W3128294524 cites W2770828094 @default.
• W3128294524 cites W2777461561 @default.
• W3128294524 cites W2785934310 @default.
• W3128294524 cites W2791483720 @default.
• W3128294524 cites W2792821195 @default.
• W3128294524 cites W2793873799 @default.
• W3128294524 cites W2794621764 @default.
• W3128294524 cites W2797203065 @default.
• W3128294524 cites W2797675588 @default.
• W3128294524 cites W2798107196 @default.
• W3128294524 cites W2801307887 @default.
• W3128294524 cites W2801309612 @default.
• W3128294524 cites W2887016314 @default.
• W3128294524 cites W2891951654 @default.
• W3128294524 cites W2897898885 @default.
• W3128294524 cites W2901107610 @default.
• W3128294524 cites W2902536275 @default.
• W3128294524 cites W2914311347 @default.
• W3128294524 cites W2919091706 @default.
• W3128294524 cites W2923049878 @default.
• W3128294524 cites W2925446385 @default.
• W3128294524 cites W2951934596 @default.
• W3128294524 cites W2953757801 @default.
• W3128294524 cites W2959497269 @default.
• W3128294524 cites W2964228416 @default.
• W3128294524 cites W2964607730 @default.
• W3128294524 cites W2972212968 @default.
• W3128294524 cites W2972582992 @default.
• W3128294524 cites W2991567947 @default.
• W3128294524 cites W2992931937 @default.
• W3128294524 cites W2994532040 @default.
• W3128294524 cites W2995437528 @default.
• W3128294524 cites W3021598078 @default.
• W3128294524 cites W3026202285 @default.
• W3128294524 doi "https://doi.org/10.7150/thno.52435" @default.
• W3128294524 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7847666" @default.
• W3128294524 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33537094" @default.
• W3128294524 hasPublicationYear "2021" @default.
• W3128294524 type Work @default.
• W3128294524 sameAs 3128294524 @default.
• W3128294524 citedByCount "50" @default.
• W3128294524 countsByYear W31282945242021 @default.
• W3128294524 countsByYear W31282945242022 @default.
• W3128294524 countsByYear W31282945242023 @default.
• W3128294524 crossrefType "journal-article" @default.
• W3128294524 hasAuthorship W3128294524A5006148444 @default.
• W3128294524 hasAuthorship W3128294524A5014030303 @default.
• W3128294524 hasAuthorship W3128294524A5019707913 @default.
• W3128294524 hasAuthorship W3128294524A5023113049 @default.
• W3128294524 hasAuthorship W3128294524A5030908494 @default.
• W3128294524 hasAuthorship W3128294524A5043713844 @default.
• W3128294524 hasAuthorship W3128294524A5064711465 @default.
• W3128294524 hasAuthorship W3128294524A5081953823 @default.
• W3128294524 hasAuthorship W3128294524A5082553528 @default.
• W3128294524 hasAuthorship W3128294524A5083090225 @default.
• W3128294524 hasAuthorship W3128294524A5086271283 @default.
• W3128294524 hasAuthorship W3128294524A5088114400 @default.
• W3128294524 hasBestOaLocation W31282945241 @default.
• W3128294524 hasConcept C121608353 @default.

• next